Register
Bursectomy offers no survival advantage over omentectomy in resectable gastric cancer |
Journal Updates
eMediNexus Coverage from: 
Bursectomy offers no survival advantage over omentectomy in resectable gastric cancer
eMediNexus,  16 May 2018
remove_red_eye 555 Views
#General Surgery #Hematology #Oncology #Pathology and Lab Medicine #Pharmacist


comment                   
        



Bursectomy offers no survival advantage over non-bursectomy (omentectomy) concluded a phase 3, open-label, randomised controlled trial reported online April 27, 2018 in The Lancet Gastroenterology & Hepatology. As per the researchers, D2 lymph node dissection with omentectomy alone should be done as a standard surgery for resectable cT3–T4a histologically proven gastric adenocarcinoma.


Comments

Comments on eMediNexus are moderated. We retain the right to remove any comments at our sole discretion.